Supriya Lifescience Ltd

NSE: SUPRIYA · Pharmaceuticals · sector

₹833.05NSE close 2026-10-26

Key numbers

Market cap₹6,705 cr

Price₹833.05

52w high / low₹1,085 / ₹546

P/E33.8xSector median 27.9x

P/B5.6xSector median 2.9x

Book value₹148.8

Dividend yield0.12%Sector median 0.48%

ROE18.1%Sector median 11.7%

ROCE22.5%Sector median 12.3%

OPM33.2%Sector median 14.0%

Debt / equity0.00xSector median 0.16x

EV/EBITDA22.9xSector median 18.6x

Interest cover154.2x

Current ratio4.40x

Sales growth 3y+21.6%Sector median +9.6%

Profit growth 3y+32.5%Sector median +13.3%

PEG1.04x

Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹79 cr vs borrowings ₹0 cr (FY26): cash is higher (net cash).
Operating profit covered interest 154.2x in the last 12 months.
Operating cash flow was below net profit in 5 of the last 5 years (FY26, FY25, FY24, FY23, FY22).
Revenue was higher than a year earlier in 4 of the last 4 quarters.
Other income was 6% of net profit in the last 12 months.
Debtor days went from 71 (FY24) to 97 (FY26).
Dividend paid in 4 of the last 5 financial years.
Price ₹833.05 on 2026-10-26: -23.2% from the 52-week high, +52.7% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹1,009.30 · low ₹516.85

Quarterly results

₹ cr	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	166	186	184	145	200	206	277	190
EBITDA	65	66	68	52	73	72	98	47
OPM %	39.0%	35.5%	36.7%	35.6%	36.4%	34.7%	35.3%	25.0%
Other income	3	2	3	3	3	3	3	3
Net profit	46	47	50	35	50	50	74	24
EPS (₹)	5.71	5.82	6.29	4.32	6.27	6.17	9.22	2.99
Revenue YoY					+20.3%	+11.2%	+50.2%	+30.8%
Profit YoY					+9.3%	+6.2%	+47.3%	-30.9%

Standalone figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY22	FY23	FY24	FY25	FY26	TTM
Revenue	530	461	570	696	828	873
EBITDA	214	129	173	261	294	289
Net profit	152	90	119	188	209	198
EPS (₹)	18.86	11.16	14.80	23.35	25.98	24.65
Revenue growth		-13.0%	+23.7%	+22.1%	+18.9%	+28.1%
Profit growth		-40.8%	+32.6%	+57.8%	+11.3%	+11.4%
Dividend / share (₹)	–	0.60	0.60	0.80	1.00

Compounded growth	3 years	5 years	Last 12 months
Sales	+21.6%	–	+28.1%
Net profit	+32.5%	–	+11.4%
EPS	+32.5%	–	–
Share price	–	+25.0% (2y)	+11.7%

Balance sheet

₹ cr	FY22	FY23	FY24	FY25	FY26
Shareholders' equity	–	699	815	997	1,198
Borrowings	–	17	0	0	0
Cash & equivalents	–	158	75	79	79
Total assets	–	820	921	1,112	1,357
Fixed assets	–	255	304	451	683
Capital work in progress	–	68	149	148	36
Investments	–	25	64	63	99
Receivables	–	85	112	134	219
Inventory	–	116	85	118	160
Payables	–	64	60	0	111

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY22	FY23	FY24	FY25	FY26
Cash from operations	49	66	113	165	186
Cash from investing	-60	-133	-174	-152	-176
Cash from financing	150	-3	-22	-8	-10
Capex	60	108	146	162	152
Free cash flow	-11	-42	-32	2	34

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY22	FY23	FY24	FY25	FY26
ROE %	–	12.8%	14.6%	18.9%	17.5%
ROCE %	–	17.7%	20.6%	25.1%	23.1%
Debtor days	–	67	71	70	97
Inventory days	–	234	140	205	229
Payable days	–	130	98	0	159
Cash conversion cycle (days)	–	171	113	275	167
Working capital days	–	292	205	186	181

Shareholding

Holder	% (2026-09-30)
Promoters	68.30%
FIIs	6.44%
DIIs	5.47%
of which Mutual funds	1.28%
of which Insurance	2.37%
Public (non-institutions)	19.79%

Quarter	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters %	68.30%	68.30%	68.30%	68.30%	68.30%	68.30%	68.30%	68.30%

Promoter group	%
Satish Waman Wagh	67.64%
Smita Satish Wagh	0.40%
Saloni Satish Wagh	0.13%
Shivani Satish Wagh	0.13%
Arun Waman Wagh	0.00%
Satish Waman Wagh Partner representing SupriyaPharmaceuticals	0.00%

Public holders above 1%	%
Cohesion MK Best Ideas Sub-trust	3.17%
Aditya Birla SUN Life Insurance Company Limited	2.16%

78,561 shareholders. Pledged: – of promoter shares.

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
SUPRIYA	₹6,705 cr	33.8x	5.6x	18.1%	22.5%	33.2%	+21.6%	0.12%

All 185 companies in Pharmaceuticals →

Dividends & corporate actions

Ex-date	Action	Detail
2026-09-04	Dividend	Dividend - Re 1 Per Share
2025-09-04	Dividend	Dividend - Re 1 Per Share
2024-09-20	Dividend	Annual General Meeting/Dividend - Rs 0.80 Per Share
2023-09-15	Dividend	Annual General Meeting/Dividend - Re 0.60 Per Share
2022-09-01	Dividend	Annual General Meeting/Dividend - Re 0.60 Per Share

Documents

Links go to the original files on the exchange website.

About the company

Manufacturing of Active Pharmaceutical Ingredients: Manufacturing of Active Pharmaceutical Ingredients


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	SUPRIYA
BSE code	543434
ISIN	INE07RO01027
Face value	₹2.0
Incorporated	2008-03-26
Website	www.supriyalifescience.com
Plants (India / abroad)	3 / 0

From the company's filings (BRSR FY26).

Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.